Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Happy Bithday !
Henry
@HenryMuney
#Flaskworks patent application with issuance payment on October 1, 2024 and notice of allowance of August 1, 2024: RU2022113534 - "Systems and methods for cell culturing"
Next step: Patent issuance.
$NWBO
No problem !
GLTU
Of course I know that.
I only answered his question: dollars or Dmark?
GLTU
See new posts
Conversation
Peter Davis
@peter_brit
#dcvax $nwbo #gbm
Pardon the Radio Silence
What Can't Dendritic Cells Do?
Stillwell888
Oct 1
Happy Q4! I know itโs been a little while since the last Bamboo Lounge article, but we are toiling away on a few pieces. Two have been completed but the timing is not right for release. Another is underway on a company with very positive P3 data for a rare cancer that is oddly being forced by the FDA to do another trial. Lastly there is one about a small pharmaceutical with positive trial data that has been relentlessly attacked by the shorts. The article on the latter may not happen as the CEO is reticent to risk the ire of the shorts and draw attention to his company but it looks like unless he does something, it will be in serious trouble.
On the NWBO front it is is radio silence from the company as shareholders, doctors, patients and defendants await news from the MHRA on the MAA and from Judge Stein in the Southern District on New York on the motion-to-dismiss. If we had to bet, weโd say news on the latter comes first.
There are various news items and posts on X that have been interesting. One which caught my eye lined to an article in National Medical Library entitled โEmerging Roles for Dendritic Cells in Heart Failureโ
DC's in Heart Failure
Itโs an interesting piece on on a new field called cardio-immunology. From the article:
โThe field of cardio-immunology has emerged from discoveries that define roles for innate and adaptive immune responses associated with myocardial inflammation and heart failure. Dendritic cells (DCs) comprise an important cellular compartment that contributes to systemic immune surveillance at the junction of innate and adaptive immunity.โ
This is yet another article about the critical role dendritic cells play in maintaining human health. While NWBO is not active in this nascent field, the company is the leader in dendritic cell technology and know-how. But if the company has the success in the field of cancer that many expected it wonโt be long before its technology is used for things like heart disease, auto-immune diseases and other afflictions. It increasingly looks like NWBO is not a company with a treatment for cancer but one that will be a major player in dendritic based cell therapies.
While those stories percolate, weโre going to take a few days off and go fishing. Thereโs a group of four of us who try to meet every year, which weโve dubbed Fish Club, and try and catch the fall run of the striped bass. This migration, which may be the largest in the animal kingdom, was documented in a book called โOn The Runโ:
On The Run
There are several methods to try and catch a striped bass. These include using a floating lure called a popper, another is to use a sinking lure called a spoon and jig (bouncing the lure up and down off the bottom). You can also use bait like bunker (menhaden), herring or a live eel. Eels tend to work the best, but inflation has also hit bait prices and now an eel goes for $2! A tip for eels would be appreciated!
Tips for Eels
We also fish for other species including black sea bass, bluefish and tautog. But the one I really like to catch is the false albacore. A member of the tuna family, they are inedible but fight like hell when caught. The weather forecast is good and itโs a new moon so hoping the fishing is good.
Unless something unexpected happens, the next article will be sometime next week.
https://substack.com/[@ userid=149621873]
Gregory Zivic, MD
@metacollectiveG
ยท
2h
$NWBO I think thereโve been a huge number of patients treated under the Specials Program. I believe their data is being collected to prove response rates will suffice in morphing the P2 trials of the Roswell technology and the combination trials into P3s using the same endpoints.
Gregory Zivic, MD
@metacollectiveG
ยท
5h
$NWBO Itโs my belief that as of end of August thereโs been some real Wall Street analysis in gear and weโll see a steady, albeit slow, value discovery of the in licensed pipeline from Roswell Park as well as other coming news prior to MAA approval.
Is this hyper active dendritic that we have talking about it ?
Just found this:
Justin Keister MS DABR
@justinkeister5
Optimal. Finding DCs that are optimally activated is key to triggering the best immune response. $NWBO
GLTU
Sorry Zadie, i don't know.
Anybody?
GLTU
$NWBO patent application with status "Grant of patent is intended" on September 25, 2024 by the European Patent Office (EPO) - "Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response"
https://patentscope.wipo.int/search/en/detail.jsf?docId=EP215640992
GLTAL
Captain,
Thanks to biosectinvestor :
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173914763
GLTU
Thanks for this interesting post ATL.
It would be something if the CI (with still very nasty side effects) could be replaced by vitamin C.
GLTU
alphapuppy,
I think it is about the safe reduction of tumor size over time.
So far it seems that only DCvax and chemo/rad can really get to the tumor and damage the antigens and even eliminate them.
The big difference is that DCvax does this completely without any harmful side effects while chemo/rad is a horror for the entire body.
So giving DCvax and then watching the reduction, over time, of tumor size can be a blessing in disguise.
GLTU
"But we would now like to do some more focused, faster path, tumor shrinkage endpoint trials. So we are, as we evaluate, I mean, we have so many opportunities in front of us now. Really, the challenge is choosing. Right? And so we we gotta steer ourselves, to the extent we can, towards that direction, to more shrinkage endpoints".
And combining these tumor response trials with the tumor agnostic, offers far-reaching possibilities.
Right?
GLTU
Hereโs a brief summary.
1. DCVax activates T cells to fight the cancer tumor. It is very effective but the effect is mitigated somewhat by a tumor defense. The tumor sends out PD-L1 proteins to attach to the T cellโs PD-1 receptor. When activated, this is a checkpoint that down-regulates the T cell.
2. So, a PD-1 inhibitor, aka checkpoint inhibitor (CI), neo-adjuvant drug was added. It is very effective in fighting this tumorโs defense.
(Thanks to Chiugray).
No trading in NWBO ??
Thank you lykiri.
GLTU
🇩🇰 The Danish Dude 🇩🇰
@FlemmingBruce
$NWBO
She not only was a finalist, she WON New York Law Journalโs Attorney of the Year Award for 2024.
And under a year ago, she was appointed president of the Institute for Law and Economic Policy.
Watch her gobble up 7 market makers RAW!
https://twitter.com/FlemmingBruce/status/1833439231621931285/photo/1
" That would look like a different company indeed ".
Exactly what LP said in the last ASM.
GLTU
The network here in Holland is also getting bigger and bigger.
In the past few days minions were added and 200 k were bought.
In total now many more people than a few months before.
GLTU
"And yet, any (potential) lock up would need to be published, for regulatory reasons. So as far as Iโm concerned, NWBO is foot loose and fancy free to consider offers from any larger bidders. What if Eli or Novo make any (potential) bid public"?
Then all hell breaks loose I think!
Wonderful.
GLTU
Thanks laser,
The only thing NWBO does NOT own is the land, the building and the employees. The land and the building is, we can safely say, contrary to what the nay sayers say, that the vast majority of Advent's turnover goes to NWBO and of course the large profit margin as well.
Too bad for the short family.
" At September 30, 2019, the Company had operating lease liabilities of approximately $4.9 million for both the 20-year lease of the building for the manufacturing facility in Sawston, U.K., and the current office lease in the U.S. and ROU of approximately $4.5 million for the Sawston lease and US office lease, which were included in the condensed consolidated balance sheet " .
https://www.sec.gov/Archives/edgar/data/1072379/000110465919062726/tm1919565d1_10q.htm
GLTAL
I wrote : a total of $ 60 B.
GLTU
I think Advent alone is worth $20B considering what has been paid on the market for a major, well-functioning CDMO.
With that a very high P/E, considering the enormous growth potential I would say 40.
Revenues cannot be estimated but with approximately (wild guess) 5000 patients per year for Glio 3/4 alone to start in the UK, for let's say $150,000 pp, that is let's say 1B.
Then I come to an estimate of a total of $60B in the not too distant future.
GLTU
Henry
@HenryMuney
$NWBO Patent granted on September 2, 2024 - 🇮🇱 IL256522 - "Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response"
https://patentscope.wipo.int/search/en/detail.jsf?docId=IL214953959
10:42 PM ยท Sep 3, 2024
ยท
1,780
Views
Thank you Captain for your good work!
GLTU
And ofcourse we have this one Doc logic:
" Apparently, according to this article that was published last week on 1/15/2024, researchers at UCLA, including Dr. Linda Liau, Dr. Timothy Cloughesy and Dr. Phionah NghiemPhu, have been able to use CRISPR gene editing technology to change unmethylated GBM patients into methylated GBM patients".
ATL: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173680608
GLTU.
Peter Davis
@peter_brit
#dcvax $nwbo #gbm
Tumour-agnostic oncology โ time has come to re-think clinical research
27 Aug 2024
Advances in precision oncology are moving the field towards a biology-based cancer care, and ESMO is supporting the change with a series of tailored resources for medical oncologists
📷
The traditional characterisation of the disease by the organ in which it originated continues to determine how cancer care is delivered: for patients, having breast, lung or colon cancer defines which hospital department and doctor they will be referred to and, in the majority of cases, which treatments and clinical trials they will have access to. A comment in Nature recently illustrated how the organ-based classification of cancers and sequential testing of new medicines in defined tumour types has delayed patientsโ access to innovative treatmentsโin some cases by several years. โWe urgently need a new approach to classifying oncological diseases, to bring clinical research in line with modern oncology, cutting down costs and resources,โ says Prof Fabrice André, Director of Research at Gustave Roussy Cancer Campus in France, co-author of the above-mentioned article and ESMO President-Elect.
Tissue-agnostic research is an emerging field founded on the observation that sometimes the molecular determinants of response to a medicine can be shared between cancers. Conducting tumour-agnostic trials holds the promise of expediting clinical research while containing costs. โHowever, the implementation of this type of approach has so far been limited by the lack of a standard methodology for pharmaceutical companies to design their registration trials and for regulators to be able to issue tumour-agnostic approvals,โ explains André. โCrucial questions include, for example, how many patients should be enrolled for each tumour site, how to define the relevant biomarker, and how to test whether some cancers should be excluded from the approval.โ
ESMO is working actively in this area, and the release of the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S) for assessing the tumour-agnostic potential of molecularly guided therapies could contribute to a common understanding among regulators and the clinical research community of the conditions in which tissue-agnostic development should be preferred to conventional trials. (Ann Oncol. 2024; Articles in press) Going forward, more research will also be necessary to develop standard criteria for defining when a biomarker can be considered as tumour-agnostic in the first place.
Preparing the wider ecosystem to support the change
The body of knowledge available on the genomic landscape at DNA level across cancers, André argues, is now mature enough to support such a shift. Rapid scientific and therapeutic advances are also what prompted ESMO to update its recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer earlier this year (Ann Oncol. 2024; Articles in press). Among other developments, testing recommendations have been extended to various new tumour types including rare cancers, covering both ESCAT tier I alterations and tier II investigational biomarkers, as well as selected tumour-agnostic biomarkers where patients have access to matched therapies.
But is the oncology community ready to become tumour-agnostic? โPatients themselves are increasingly demanding rapid access to targeted therapies. The question of the fieldโs maturity for tissue-agnostic research is not about whether people are going to agree or not, but rather โwhat is the benefit for the patient?โ,โ André highlights.
Cancer care evolution towards a tumour-agnostic approach comes with the need for a change in education for medical oncologists. For André, the era when clinicians simply needed to know how to interpret a clinical trial is over. โToday oncologists also need a strong background in biology and a deep understanding of the molecular and cellular mechanisms of diseaseโknowledge that is indispensable for them to integrate and implement information they receive both in genomic reports and in reporting of future biomarker-driven, tissue-agnostic trials,โ he says. ESMO has a key role to play in producing and disseminating advanced learning resources and continuing education in the so-called molecular oncology, and André believes that also patients should be part of this process.
โImportantly, patients need to be educated in this new era of cancer care and learn to perceive their cancer by its molecular mechanism rather than by the location of the tumour. This may help them understand why they are receiving one treatment rather than another, and feel more engaged in clinical research,โ he concludes.
Griffin and his brothers in crime with their spoofing manipulations ( and therby naked shorting) are the reason for the shareprice.
And not the management with all the milestones achieved and dodging the Wall Street Mafia TO BANKRUPT THEM and not the dilution. .
We will have the 100% proof out soon.
Congrats ATL,
I'm sure it all will work out !
Best to you.
ilovetech,
I am of course very curious about the outcome of the Trial with Keytruda ,Poli-ICLC and DCvax !
But another 2 failures for Merck now could perhaps mean that they have finally thrown in the towel regarding their own Trials and that they finally realize that they cannot achieve anything without NWBO.
Then we finally have a BP on our side.
Best to you.
Peter Davis
@peter_brit
ยท
2h
#dcvax $nwbo #gbm
Two more Keytruda Phase 3 failures from Merck..
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
https://merck.com/news/merck-provides-update-on-phase-3-keynote-867-and-keynote-630-trials/
August 29, 2024
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and
Show more
$NWBO Just looking over the Cohen Representation for NWBIO, I still find it interesting Raymond Sarola was added to the team well into the case. Keep wondering if a whistle blower may have stepped forward?
— SemperFITrader (@SouthernDrive21) August 25, 2024
"Ray also represents clients in whistleblower matters" pic.twitter.com/uHaEhVshFq